BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 4,940 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 4,940 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40. Following the completion of the transaction, the chief executive officer owned 1,120 shares of the company’s stock, valued at approximately $303,027.20. This represents a 81.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of ONC traded down $4.56 during trading hours on Wednesday, reaching $263.61. 291,079 shares of the company traded hands, compared to its average volume of 255,249. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $28.92 billion, a PE ratio of 58.97 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The stock has a fifty day simple moving average of $301.03 and a 200 day simple moving average of $315.60.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in BeOne Medicines in the 1st quarter worth about $3,475,000. EverSource Wealth Advisors LLC boosted its stake in BeOne Medicines by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after buying an additional 52 shares during the last quarter. Royal Bank of Canada boosted its stake in BeOne Medicines by 3.5% in the 1st quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock worth $20,905,000 after buying an additional 2,399 shares during the last quarter. Finally, Rokos Capital Management LLP acquired a new stake in BeOne Medicines in the 1st quarter worth about $4,256,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on ONC shares. Royal Bank Of Canada increased their price objective on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Truist Financial reaffirmed a “buy” rating and set a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.